Boston Scientific (NYSE:BSX – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 3.430-3.490 for the period, compared to the consensus estimate of 3.460. The company issued revenue guidance of $22.2 billion-$22.4 billion, compared to the consensus revenue estimate of $22.4 billion. Boston Scientific also updated its Q1 2026 guidance to 0.780-0.800 EPS.
Boston Scientific Stock Down 2.0%
Shares of NYSE BSX traded down $1.53 during midday trading on Friday, hitting $76.11. 16,278,875 shares of the stock traded hands, compared to its average volume of 16,549,240. The company has a market cap of $112.83 billion, a PE ratio of 39.24, a P/E/G ratio of 1.33 and a beta of 0.67. The business has a 50 day moving average price of $93.90 and a two-hundred day moving average price of $98.98. Boston Scientific has a one year low of $74.86 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts predict that Boston Scientific will post 2.85 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Boston Scientific
Insider Buying and Selling
In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.50% of the company’s stock.
More Boston Scientific News
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Q4 2025 results beat consensus (growth in revenue and EPS) — the underlying quarter showed solid top-line growth that supports long‑term fundamentals. Boston Scientific Corporation 2025 Q4 – Results – Earnings Call Presentation
- Positive Sentiment: Several analysts still rate BSX as Buy/Overweight with meaningful upside potential (even after cuts) — firms such as Morgan Stanley and RBC continue to model upside, which can attract long-term buyers. Boston Scientific (NYSE:BSX) Given New $118.00 Price Target at Morgan Stanley
- Neutral Sentiment: Planned board director departure announced (governance change worth monitoring but not immediately operational). Boston Scientific announces planned board director departure
- Negative Sentiment: Management issued cautious 2026 revenue/growth commentary (guidance tone weaker than investors expected), triggering a high‑volume selloff that erased recent gains. That guidance disappointment is the principal driver of the downward price pressure. Boston Scientific shares slide on cautious 2026 revenue forecast
- Negative Sentiment: Numerous brokerages cut price targets after the quarter (JPMorgan, Evercore ISI, Wells Fargo, Needham, Truist, RBC, Baird, Mizuho, etc.), increasing near‑term uncertainty and pressuring momentum traders. Boston Scientific Analysts Cut Their Forecasts Following Q4 Results
- Negative Sentiment: CEO insider sale of roughly $15.0M in stock reported — sizable insider selling amplifies negative sentiment while the stock is under pressure. Boston Scientific (NYSE:BSX) CEO Sells $15,042,634.49 in Stock
- Negative Sentiment: Investigation notice from a plaintiff firm (Levi & Korsinsky) into potential securities-law violations creates headline risk and may keep some institutions on the sidelines. Investors in Boston Scientific Corporation (BSX) Warned of Potential Securities Fraud – Contact Levi & Korsinsky Today
- Negative Sentiment: Weakness in a key product/segment (electrophysiology / a highly promoted device) was highlighted by reporters and investors, magnifying concerns about near‑term growth execution. Boston Scientific shares fall as key segment’s performance spooks investors
Institutional Investors Weigh In On Boston Scientific
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Northern Trust Corp lifted its stake in shares of Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock valued at $1,406,129,000 after purchasing an additional 128,188 shares during the last quarter. Amundi lifted its position in Boston Scientific by 17.5% in the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after buying an additional 1,781,830 shares during the last quarter. Marshall Wace LLP boosted its stake in Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after buying an additional 2,301,383 shares during the period. Lazard Asset Management LLC increased its position in shares of Boston Scientific by 1.3% during the third quarter. Lazard Asset Management LLC now owns 6,719,769 shares of the medical equipment provider’s stock valued at $656,051,000 after acquiring an additional 87,009 shares during the last quarter. Finally, Man Group plc lifted its holdings in shares of Boston Scientific by 79.8% in the 3rd quarter. Man Group plc now owns 3,843,937 shares of the medical equipment provider’s stock worth $375,284,000 after acquiring an additional 1,706,494 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Recommended Stories
- Five stocks we like better than Boston Scientific
- Your Bank Account Is No Longer Safe
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- Wall Street’s New Sports Prediction Trade
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
